Skip to content

Application of Remimazolam in gynecological day surgery

Application of Remimazolam in gynecological day surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056240
Enrollment
Unknown
Registered
2022-02-02
Start date
2022-02-01
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynaecological diseases

Interventions

Remimazolam Group:Anaesthetic induces and maintains the use of Remimazolam
Propofol Group:Anaesthetic induces and maintains the use of propofol

Sponsors

Guilin Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients who have undergone gynecological laparoscopic surgery and who clearly understand and volunteer to participate in the study of the project, and who have signed an informed consent form by themselves; 2. Women aged 18-60 years; 3. Body mass index (BMI)18-24kg/m2kg/m2; 4. ASA classification I-II.

Exclusion criteria

Exclusion criteria: 1. Patients with acute upper respiratory tract infections and asthma attacks; 2. Patients with low blood pressure (Bp150/90mmHg); 3. Patients with liver dysfunction (child-pugh B), renal dysfunction; 4. Patients with heart disease such as severe heart rate loss, heart attack10mol/L); 11. Patients who do not meet the fasting standard and have previous stomach drain disorders.

Design outcomes

Primary

MeasureTime frame
BiS number Value;The total amount of medication;Wake up MOAA/S rating;

Secondary

MeasureTime frame
Blood pressure, heart rate and oxygen saturation;Occurrence of transient hypotension, bradycardia (heart rate <50 beats/min);Occurrence of postoperative side effects such as nausea, vomiting, dizziness, and muscle pain;Intraoperative awareness;Patient awakening time;Satisfaction level;

Countries

China

Contacts

Public ContactXiaoju Long

Guilin Medical College Hospital

515788437@qq.com+86 15507737718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026